Clinical trials: Thrombolysis
Ischemic Stroke
Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only approved acute drug treatment <4½ hours of stroke onset.
- Trial name
- NOR-TEST (NCT01949948)
- Testing
- Tenecteplase, Alteplase
- Where
- 13 sites in Norway
- Volunteers
- 1,050 people
- Sponsor
- Lars Thomassen
Ischemic Stroke
Predictors of Outcome in t-PA Treated Stroke.
Stroke is among the most disabilitating diseases worldwide in terms of numbers affected and its consequences. A relatively new and well documented treatment of acute ischemic stroke today is tPA (tissue plasminogen activator…
- Trial name
- NCT01498042
- Where
- Norway
- Volunteers
- 162 people
- Sponsor
- Sorlandet Hospital HF
Central Retinal Artery Occlusion
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.
- Trial name
- THEIA (NCT03197194)
- Testing
- Alteplase, acetylsalicylic acid
- Where
- 17 sites in France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke, Acute, Thrombolysis
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke…
- Conditions
- Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment
- Trial name
- TNK-PLUS (NCT06221371)
- Testing
- Tenecteplase, direct EVT
- Where
- 21 sites in China
- Volunteers
- 391 people
- Sponsor
- Beijing Tiantan Hospital
Sleep Apnoea, Cerebral Palsy
Ischaemic Stroke and Sleep Apnea in Northern Part of Finland
Obstructive sleep apnoea is a risk factor for ischaemic stroke. study hypothesis: In prospective study the investigators want to know how many ischaemic stroke patients have sleep apnoea and does thrombolysis play a role in…
- Trial name
- NCT01861275
- Testing
- Nasal CPAP
- Where
- Finland
- Volunteers
- 256 people
- Sponsor
- University of Oulu
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic…
- Trial name
- SIMPLIFIED (NCT07606807)
- Testing
- Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Stroke
CT Based Definition of a Tissue Window for Acute Stroke Thrombolysis
Aim of this study is to define a CT-based "tissue window" for stroke thrombolysis. Our primary hypothesis is that 1. patients with a "tissue window" (favourable non-contrast CT (NCCT) scan and an intracranial occlusion on CT…
- Trial name
- CT-DEFINE (NCT00463281)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Technische Universität Dresden
Ischemic Stroke, Thrombolytic Therapy
Mild Hypothermia After Endovascular Treatment in Acute Ischemic Stroke
To study safety and feasibility of mild therapeutic hypothermia after successful recanalization by mechanical endovascular treatment in patients with acute ischemic stroke and proximal arterial occlusion.
- Trial name
- HELMET (NCT02985060)
- Testing
- Arctic Sun, Standard treatment, Saline
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pulmonary Embolism, Pulmonary Thromboembolism
The PERSEVERE Study
Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care
- Trial name
- NCT06588634
- Testing
- FlowTriever System, Standard of Care
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Inari Medical
Ischemic Stroke
Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within…
- Trial name
- TALISMAN (NCT02180204)
- Testing
- Tenecteplase, Alteplase
- Where
- United States
- Sponsor
- Reza Behrouz, DO
Acute Ischemic Stroke
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
This study is a multicentre, randomized, blinded-endpoint trial that aims to evaluate the efficacy and safety of human urinary kallidinogenase combined with reteplase intravenous thrombolysis in the treatment of acute ischemic…
- Trial name
- KREATE (NCT07483281)
- Testing
- Human Urinary Kallidinogenase, Clinical Routine Treatment
- Where
- China
- Volunteers
- 220 people
- Sponsor
- China-Japan Union Hospital
Ischemic Stroke, Acute
Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion
Iron overload has been associated with greater brain injury in ischemia/reperfusion experimental stroke models and ischemic stroke patients, especially in those treated with thrombolytic treatment.
- Trial name
- TANDEM-1 (NCT00777140)
- Testing
- Deferoxamine
- Where
- 4 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Germans Trias i Pujol Hospital
ST Elevation Myocardial Infarction
Cost Effectiveness if Primary PCI Versus Thrombolytic Therapy in Acute STEMI in Assiut University Hospital
Cost effectiveness between PPCI and thrombolytic therapy in STEMI patients without contraindications
- Trial name
- NCT03310437
- Testing
- Primary PCI
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nahed Sameh Zaki
Stroke
Safety of Intravenous Thrombolytics in Stroke on Awakening
The primary objective of this study is to evaluate the safety of intravenous tissue plasminogen activator (IV tPA) in patients waking up with symptoms of acute stroke and presenting to the Emergency Department (ED) within 4.5…
- Trial name
- SAIL-ON (NCT01643902)
- Testing
- tPA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Acute ST Segment Elevation Myocardial Infarction
Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time
Patients with acute ST-segment elevation myocardial infarction and thrombolysis indications, will be given the recombinant human prourokinase for thrombolysis treatment, and in accordance with the guidelines, will be treated with…
- Trial name
- SEPCIT (NCT03137212)
- Testing
- thrombolysis and PCI of A type, thrombolysis and PCI of B type
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Hospital of Jilin University